Conferences
SUO 2017: The Probability Of Indolent Versus Aggressive Histology Based On Renal Tumor Size: Implications For Surveillance And Treatment
November 30, 2017
SUO 2017: Targeted Therapy Prior To Cytoreductive Nephrectomy For IMDC Intermediate And Poor Risk Patients
November 30, 2017
SUO 2017: The Urologist's Role in Advanced Renal Cancer
November 30, 2017
SUO 2017: Utility Of Lymph Node Dissection For Clinical Node Negative Upper Tract Urothelial Cell Carcinoma: A Multicenter Study
November 30, 2017
SUO 2017: Validation of The BCG Unresponsive Definition
November 30, 2017
SUO 2017: The Impact of The Affordable Care Act and Medicaid Expansion on Insurance Status and Cancer Staging for Bladder Cancer Patients
November 30, 2017
SUO 2017: Molecular Profile of Non-Invasive Bladder Cancer
November 30, 2017
SUO 2017: Promise of Checkpoint Inhibitors for BCG-Unresponsive NMIBC
November 30, 2017
SUO 2017: Aberrant Histology in NMIBC - What Do We Know and Not Know?
November 30, 2017
SUO 2017: High Competing Risks Minimize Real-world Utility Of Adjuvant Targeted Therapy In Renal Cell Carcinoma: A Population-based Analysis
November 30, 2017
SUO 2017: Pathologic Downstaging Following Neoadjuvant Chemotherapy In Patients With High-risk Upper Tract Urothelial Carcinoma
November 30, 2017
SUO 2017: Post-TUR Mitomycin C Debate: Should it be Standard of Care?
November 30, 2017
SUO 2017: Is Gemcitabine the Answer?
November 30, 2017
SUO 2017: Preoperative Multiplex Nomogram For Prediction Of high-risk non-organ confined Upper-Tract Urothelial Carcinoma
November 30, 2017
SUO 2017: Thermo Reversible Hydrogel Based Delivery MitoGelâ„¢ - Upper Tract Urothelial Carcinoma
November 30, 2017
SUO 2017: Post-Transurethral Resection Intravesical Mitomycin C Debate
November 30, 2017
SUO 2017: InPACT Trial - Answering the Unanswered Questions
November 30, 2017